---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-058085"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:12:13.757855+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma Q1 net loss $4.0M; initiates Phase 1b for NXP800 in ovarian cancer

## Summary
- Cash $15.5M as of March 31, 2023 vs $20.0M at Dec 31, 2022; net loss $4.0M (Q1 2023) vs $2.9M (Q1 2022).
- Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer initiated; multicenter trial with GOG Foundation and ENGOT.
- IND for NXP900 pending; first-in-human trial expected shortly after IND becomes effective.
- Mayo Clinic investigators presented in-vivo PDX data at AACR showing NXP800 potential in cholangiocarcinoma.
- Company expects cash into H2 2024; R&D expenses $2.4M (up $0.6M YoY), G&A $1.7M (up $0.6M YoY).

## SEC filing metadata
- accession: 0001104659-23-058085
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923058085/0001104659-23-058085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923058085/tm2315012d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-058085
- JSON: https://secwatch.observer/filing/0001104659-23-058085.json
- Plain text: https://secwatch.observer/filing/0001104659-23-058085.txt

## Key facts
- Earnings Releases
  Nuvectis Pharma, Inc. reported first quarter 2023 results: net income Net loss was $4.0 million for the three months ended March 31, 2023.
  - Period: first quarter 2023
  - Net income: Net loss was $4.0 million for the three months ended March 31, 2023
  - Result: reported results
  source text: Net loss was $4.0 million for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465923058085/0001104659-23-058085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.